Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2026
2026-05-14 English
S-1 - Propanc Biopharma, Inc. (0001517681) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus for the resale of common stock by a selling stockholder. The document contains detailed information about the company, the securities being registered, risk factors, management discussion, and other disclosures typical of a registration statement. This type of filing is related to capital raising activities and financing. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual or quarterly report, audit report, earnings release, or any other category defined in the list. It is a primary registration statement for securities offering, which is best classified under Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the filing itself, not just an announcement.
2026-04-10 English
PRE 14A - Propanc Biopharma, Inc. (0001517681) (Filer)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed with the SEC, which is used to notify shareholders of corporate actions approved by written consent rather than at a meeting. The content details the issuance of restricted shares to officers, directors, and service providers, as well as a reverse stock split. It references NASDAQ listing rules requiring shareholder approval for these actions. The document explicitly states it is an Information Statement pursuant to Section 14(c) of the Securities Exchange Act of 1934 and is not soliciting proxies. This type of filing is a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to inform them of corporate actions and to comply with regulatory requirements for shareholder approval, but does not itself constitute a meeting or vote. The document is lengthy (15,000 characters) and contains substantive information, not merely an announcement or certification. Therefore, the correct classification is PSI with high confidence.
2026-03-19 English
8-K - PROPANC BIOPHARMA, INC. (0001517681) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 20, 2026, by Propanc Biopharma, Inc. The key content is the announcement of a change in the company's board of directors: Dr. Julian Kenyon retired and Dr. Ralf Brandt was appointed to the Board. This is clearly an announcement of a board/management change. There are no financial statements or detailed financial data presented, and the document is not an annual or quarterly report. The primary focus is on management changes, fitting the Board/Management Information category (MANG).
2026-02-26 English
10-Q Filing
Interim / Quarterly Report Q2 2026
2026-02-17 English
S-1 Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC by Propanc Biopharma, Inc. It is a registration statement under the Securities Act of 1933 for the resale of shares by a selling stockholder. The text includes a preliminary prospectus, details about the offering, risk factors, management discussion, and other typical sections of a registration statement. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2026-02-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.